Business Wire

Mavenir Enables Faster 5G Service Creation with its BSS Digital Enablement Platform

21.7.2021 16:00:00 EEST | Business Wire | Press release

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud infrastructure and transforms the way the world connects, today announced its Business Support System (BSS) solution called Mavenir Digital Enablement (MDE) platform. The MDE Platform enables Communications Service Providers (CSPs) to quickly and easily build new digital offerings through a simplified graphical service experience creator. MDE can be deployed either as a standalone BSS or as an overlay on the CSP’s legacy BSS.

This solution uses a proven Microservices, API-first, Cloud-Native, Headless (MACH) architecture that is aligned with TM Forum’s Open Digital Architecture (ODA) and OpenAPIs. Its low/no-code UI enables agile experience creation. With a unified product catalog, MDE lets CSPs easily develop and deploy new services, speeding both time to market and time to revenue. The solution also provides tools for consolidation and transformation of network usage and non-usage data, which generates insightful information to help deliver hyper-personalized services and offerings through an omnichannel experience.

Mavenir’s unique technology enables a “composable” BSS architecture so CSPs can design their own BSS solution by assembling the right mix of microservices from the MDE library. It is designed to help CSPs innovate fearlessly without being restricted by the inflexibility of legacy BSS or IT systems. It also enables them to leverage their existing BSS/IT infrastructure by deploying the MDE Marketplace as an overlay solution. Use cases include:

  • Delivering greenfield MNO services
  • Enabling a digital marketplace for bundling CSP services with partner services to generate new revenue streams
  • Introducing a sub-brand in response to digital attacker brands or to address a niche segment of the market
  • Launching a new MVNO service by utilizing the MDE BSS as a Mobile Virtual Network Enabler (MVNE)

The MDE BSS platform can quickly and easily be deployed as an adjunct solution to launch new business services such as:

  • 5G FWA/eMBB/AR/VR services
  • IoT services for B2C/B2B/B2B2X customers
  • Connectivity bundles for B2B customers
  • Unified communication (UCC) and contact center for B2B customers
  • Rich Business Messaging using RCS for B2B customers

“Mavenir’s MDE platform enables CSPs to deliver the promise of 5G and speed up the return on their 5G investments by eliminating perpetually slow processes and the barriers of cost and time from legacy BSS,” said BG Kumar, President Communications Services at Mavenir. “Through its open APIs, MDE easily integrates with existing IT or BSS systems and can run as an overlay solution, giving CSPs the option to escape existing vendor lock-in and freedom from development limitations on legacy IT systems.”

The solution is currently deployed with various CSPs in APAC, Europe, and the Americas.

Supporting documents:

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.

www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maryvonne Tubb
Mavenir
PR@mavenir.com

Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com

Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye